BioCentury
ARTICLE | Emerging Company Profile

Cartesian expanding therapeutic window, disease settings for CAR T

CAR T therapy for myasthenia gravis shows strong efficacy, though questions remain about durability

May 13, 2022 9:58 PM UTC

Cartesian’s use of mRNA to drive expression of CARs in cell therapies may reduce the amplifying effect of DNA-based CAR therapies and associated toxicity, making its treatments more amenable to indications beyond cancer.

Launched in 2016, Cartesian Therapeutics Inc. is using mRNA, rather than lentiviral or CRISPR-based DNA engineering methods, to express the chimeric antigen receptor (CAR) in its cell therapies...

BCIQ Company Profiles

Cartesian Therapeutics Inc.